Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies

Giovanni Staurenghi,1 Nicolas Feltgen,2 Jennifer J Arnold,3 Todd A Katz,4 Carola Metzig,5 Chengxing Lu,4 Frank G Holz,6 for the VIVID-DME and VISTA-DME study investigators

ABSTRACT

Background/aims To evaluate intravitreal aflibercept versus laser in subgroups of patients with baseline Diabetic Retinopathy Severity Scale (DRSS) scores ≤43, 47, and ≥53 in VIVID-DME and VISTA-DME.

Methods Patients with diabetic macular oedema were randomised to receive intravitreal aflibercept 2 mg every 4 weeks (2q4), intravitreal aflibercept 2 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photoacoagulation at baseline with sham injections at every visit. These post hoc analyses evaluate outcomes based on baseline DRSS scores in patients in the integrated dataset. The 2q4 and 2q8 treatment groups were also pooled.

Results 748 patients had a baseline DRSS score based on fundus photographs (≤43, n=301; 47, n=153; ≥53, n=294). At week 100, the least squares mean difference between treatment groups (effect of intravitreal aflibercept above that of laser, adjusting for baseline best-corrected visual acuity) was 8.9 (95% CI 5.99 to 11.81), 9.7 (95% CI 5.54 to 13.91), and 11.0 (95% CI 7.96 to 14.1) letters in those with baseline DRSS scores ≤43, 47, and ≥53, respectively. The proportions of patients with ≥2 step DRSS score improvement were greater in the intravitreal aflibercept group versus laser, respectively, for those with baseline DRSS scores of ≤43 (13% vs 5.9%), 47 (25.8% vs 4.5%), and ≥53 (64.5% vs 28.4%).

Conclusions Regardless of baseline DRSS score, functional outcomes were superior in intravitreal aflibercept-treated patients, demonstrating consistent treatment benefit across various baseline levels of retinopathy.

Trial registration numbers NCT01331681 and NCT01363440, Post-results.

INTRODUCTION

Diabetic retinopathy (DR) is the most common microvascular complication in patients with diabetes mellitus (DM), and is the leading cause of blindness in working-age adults.1 2 Diabetic macular oedema (DME), which can occur at any stage of DR, is a major cause of vision loss in patients with DR.3

Based on the results of recent clinical trials, treatment with anti-vascular endothelial growth factor (VEGF) agents has increasingly replaced laser photoacoagulation as the standard of care in DME. Several clinical trials have demonstrated the efficacy and safety of intravitreal ranibizumab in the treatment of DME.4-6 Similar results were obtained in studies of intravitreal bevacizumab6 7; however, bevacizumab is not licensed for ophthalmic use. In the VIVID-DME and VISTA-DME studies, patients with DME who were treated with intravitreal aflibercept monotherapy achieved superior visual and anatomical outcomes compared with patients who received laser monotherapy.8 9 A comparative effectiveness study conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) demonstrated statistical significance of intravitreal aflibercept over ranibizumab or bevacizumab in patients with DME at 12 months, the primary endpoint of the study, particularly in those with a baseline visual acuity of 20/50 or worse.10 At 2 years, the visual gains achieved with intravitreal aflibercept were statistically superior to bevacizumab but the statistical superiority to ranibizumab was no longer evident.11 An area under the curve analysis showed that mean change in visual acuity over 2 years was greater with intravitreal aflibercept than with bevacizumab or ranibizumab.12

The Early Treatment Diabetic Retinopathy Study (ETDRS) was a clinical trial sponsored by the National Eye Institute in which patients were randomised to treatment with early or deferred photocoagulation, a study design which allowed observation of the natural course of DR in the initially untreated eye. The study found that severity of intraretinal microvascular abnormalities, haemorrhages and/or microaneurysms, and venous beading on fundus photographs were the most important factors in predicting the progression of DR. Based on these findings, the authors developed a Diabetic Retinopathy Severity Scale (DRSS) that divides DR into 13 levels ranging from absence of retinopathy to severe retinopathy including vitreous haemorrhage (table 1). This scale can be used to describe overall retinopathy severity as well as the change in severity over time.13 According to the American Academy of Ophthalmology, DRSS scores are associated with the risk of developing proliferative DR (PDR). The risk of developing early PDR after 1 year is low (5.4–11.9%) in patients with a DRSS score ≤43, moderate (26.3%) in patients
Severity categories for characteristics graded in multiple fields are of the form ‘maximum severity/extent’, where maximum severity can be absent (A), questionable (Q), definitely present (D), moderate (M), severe (S), or very severe (VS), and extent is the number of fields at that severity level. For example, M/2–3 grade in ≥1 field means that there are two or three fields from fields 3 to 7 with moderate severity, and none with higher severity.

ETDRS, Early Treatment Diabetic Retinopathy Study; DR, diabetic retinopathy; FPD, fibrous proliferations disc; FPE, fibrous proliferations elsewhere; HE, hard exudates; H/MA, haemorrhages/microaneuroms; IRMA, intraretinal microvascular abnormalities; NPDR, non-proliferative DR; NVD, new vessels disc (within one disc diameter of disc margin); NVE, new vessels elsewhere (>1 disc diameter from disc); PDR, proliferative DR; SE, soft exudates; VB, venous beading; VH, vitreous haemorrhage; PRH, preretinal haemorrhage.

with a DRSS score of 47, and high (50.2%) in patients with a DRSS score ≥53.14

To the best of our knowledge, no studies have examined the relationship between baseline DRSS scores and outcomes in patients with DME treated with anti-VEGF agents. Here, we report on the impact of baseline DRSS scores on functional and anatomical outcomes in patients enrolled in the VIVID-DME and VISTA-DME studies.

**METHODS**

**Design**

The study design and methods have been published previously.8 9 Key details are summarised here. VIVID-DME (NCT01331681) and VISTA-DME (NCT01363440) were phase 3, randomised, double-masked, active-controlled, 148 week trials comparing two dosing regimens of intravitreal aflibercept with laser for the treatment of DME. The studies were conducted at 127 sites in the USA, Europe, Japan, and Australia, and were conducted in accordance with the principles of the Declaration of Helsinki and International Conference on Harmonisation.

**Participants**

Adult patients with type 1 or type 2 diabetes mellitus who presented with central-involved DME (defined as retinal thickening involving the 1mm central subfield thickness) were included if best-corrected visual acuity (BCVA) was between 73 and 24 letters (20/40–20/320 Snellen equivalent) in the study eye. Only one eye per patient was included.

**Randomisation and treatment**

Patients were randomised 1:1:1 to treatment with intravitreal aflibercept 2mg every 4 weeks (2q4), intravitreal aflibercept 2mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline with sham injections at every visit. Eyes in the 2q8 group received sham injections on non-treatment visits. From week 24, additional active treatment (laser in the intravitreal aflibercept groups and intravitreal aflibercept in the laser group) was allowed in the case of disease recurrence/worsening based on prespecified criteria.

**Outcomes**

The primary efficacy endpoint for the VIVID-DME and VISTA-DME studies was the change from baseline in BCVA in ETDRS letters at week 52.
Table 3 Unadjusted mean (SD) change in BCVA by baseline DRSS score at week 52 and week 100

| Week 52          | Intravitreal aflibercept (n=249) | Laser (n=249) | Week 100 | Intravitreal aflibercept (n=499) | Laser (n=499) |
|------------------|----------------------------------|---------------|----------|----------------------------------|---------------|
| Low risk (DRSS ≤43) | 1.3 (11.2)                      | 0.0 (12.7)     | 1.3 (11.6) | 10.3 (8.7)                       | 10.0 (6.7)       |
| Moderate risk (DRSS =47) | 0.0 (12.7)                      | 0.5 (14.5)     | 0.5 (12.9) | 12.8 (9.5)                       | 12.1 (9.5)       |
| High risk (DRSS ≥53) | 0.5 (11.3)                      | 0.9 (12.7)     | 0.9 (12.9) | 12.8 (9.5)                       | 12.1 (9.5)       |

Only those with gradable baseline DRSS scores are included. BCVA, best-corrected visual acuity; DRSS, Diabetic Retinopathy Severity Scale.

Here we report on the impact of baseline DRSS score (low risk (≤43), moderate risk (47), and high risk (≥53)) on outcomes for patients enrolled in VIVID-DME and VISTA-DME. Colour fundus photography was performed at baseline, week 24, week 52, week 72 (VISTA-DME) or week 76 (VIVID-DME), and week 100. Images were evaluated by masked graders at independent reading centres. Fundus images were evaluated by the Vienna Reading Centre, Vienna, Austria (VIVID-DME) and the Digital Angiography Reading Centre, Great Neck, New York, USA (VISTA-DME). Images for 114 patients were categorised as ‘ungradable.’ The remaining patients were stratified into three subgroups based on baseline DRSS score: low risk (≤43), moderate risk (47), and high risk (≥53).

For these post hoc analyses, data from VIVID-DME and VISTA-DME have been integrated. Results of statistical analyses are presented for pooled intravitreal aflibercept and laser treatment arms.

Statistics
Patients included in the efficacy analyses are those from the full analysis set (FAS) in both studies (VIVID-DME and VISTA-DME), which includes all randomised patients who received any study medication and had at least one baseline and one postbaseline assessment. The FAS was analysed as randomised. Baseline DRSS scores were stratified into three subgroups: low risk (≤43), moderate risk (47), and high risk (≥53). Patients without baseline DRSS scores (missing or ‘ungradable’ cases as mentioned above) were not included in the analyses. For continuous endpoints such as change from baseline BCVA, an analysis of covariance model was fitted with baseline BCVA, baseline DRSS subgroup, treatment group, study, and the interaction between baseline DRSS subgroup and treatment as the fixed effect. Nominal p values were presented in these ad hoc analyses without further multiplicity adjustment. For binary endpoints, such as proportion of patients who gained or lost ≥15 letters, the counts and percentages were calculated for each treatment group.

Missing values in the outcomes were imputed using the last observation carried forward method, and for eyes that received additional treatment, the last value before additional treatment was used for analyses.

Patients included in the safety analyses are those from the safety population in both studies, which includes all randomised patients who received any study treatment.

RESULTS
At baseline, among those with baseline DRSS scores (n=748), the proportions of patients with DRSS scores of low risk (≤43), moderate risk (47), and high risk (≥53) were 38.7%, 20.6%, and 40.7%, respectively, in the pooled intravitreal aflibercept and 43.4%, 20.1%, and 36.5% in the laser group. Baseline demographics and disease characteristics based on baseline DRSS scores are reported in table 2. On average, patients in the high-risk group were younger, with a shorter duration of diabetes, and had worse BCVA and thicker retinas at baseline. Haemoglobin A1c levels at baseline were similar across the three risk groups.

At both week 52 and week 100, unadjusted mean gains in BCVA were greater in patients in all baseline DRSS score subgroups treated with intravitreal aflibercept compared with laser-treated patients (table 3). An analysis of the least squares mean difference between treatment groups (adjusting for baseline BCVA) showed that, at both time points, the difference in treatment effect between intravitreal aflibercept and laser had some numerical increasing trend as baseline DRSS score increased, from 8.9 (95% CI 5.99 to 11.81), 9.7 (95% CI 5.54 to 13.91), and 11.0 (95% CI 7.96 to 14.1) letters in those with baseline DRSS scores ≤43, 47, and ≥53, respectively (figure 1).

At both week 52 and week 100, a greater proportion of patients in all baseline DRSS score subgroups treated with intravitreal aflibercept achieved a ≥2 step improvement in
Clinical science

DRSS score compared with laser-treated patients. Regardless of the treatment group, a greater proportion of patients in the high-risk group had a ≥2 step improvement compared with patients in the medium-risk and low-risk groups (figure 2A and B).

Similarly, at both week 52 and week 100, a greater proportion of patients in all baseline DRSS score subgroups treated with intravitreal aflibercept gained ≥15 letters in BCVA compared with laser-treated patients. Regardless of treatment group, a greater proportion of patients in the high-risk group gained ≥15 letters compared with patients in the medium-risk and low-risk groups (figure 2C and D).

At both week 52 and week 100, the proportion of patients in all baseline DRSS score subgroups who lost >0 letters in BCVA was greater in laser-treated patients compared with those treated with intravitreal aflibercept. There was no discernible pattern based on baseline DRSS score regarding loss of >0 letters in BCVA (figure 2E and F).

DISCUSSION

In this analysis, we evaluated the impact of baseline DRSS scores in patients enrolled in the VIVID-DME and VISTA-DME studies. Patients from these studies were grouped according to baseline DRSS score (which is associated with low, medium, or high risk of developing PDR), and mean changes in BCVA were evaluated for each of the subgroups. Previous studies have examined the impact of baseline characteristics such as central retinal thickness15 16 and BCVA17 on visual outcomes in patients with DME treated with anti-VEGF therapy. To the best of our knowledge, the role of baseline DRSS score on visual outcomes in such patients has not been evaluated.

The week 52 and week 100 results showed that, compared with laser, visual outcomes were superior in the intravitreal...
afibercept groups, regardless of baseline DRSS score. In all subgroups, the mean change in BCVA at both time points was greater in intravitreal afibercept-treated eyes compared with laser-treated eyes. Irrespective of baseline DRSS score (and, therefore, risk of developing PDR), the proportion of patients who gained ≥15 letters in BCVA was greater for those treated with intravitreal afibercept than with laser, while the proportion of patients who lost >0 letters in BCVA was greater in those treated with laser. These findings suggest that among patients with DME, even those with more advanced DR at baseline and a greater risk of developing PDR within 1 year, greater visual benefits were observed with intravitreal afibercept compared with laser.

The magnitude of functional improvement with intravitreal afibercept treatment was similar across baseline DRSS risk groups; however, there was a numerical increasing trend in treatment difference compared with laser as baseline DRSS score increased from low to high. There is a substantial amount of evidence showing that worse baseline visual acuity results in greater improvements in patients treated with anti-VEGF therapy; however, in the current study, the numerical increasing trend was still observed after adjustments for baseline visual acuity. This finding suggests a real difference in treatment effect based on baseline DRSS score, although this analysis was not sufficiently powered to show this definitively.

Anatomical outcomes were also superior with intravitreal afibercept, with ≥2-step improvements in DRSS score occurring in a greater proportion of patients treated with intravitreal afibercept compared with laser, regardless of baseline DRSS score. At both time points, ≥2-step DRSS improvement was greater in the subgroup of patients with baseline DRSS score ≥53 compared with the other baseline DRSS score subgroups.

Strengths of the present study include the use of masked graders from two reading centres to evaluate fundus photographs and determine baseline DRSS scores, as well as the fixed dosing and strict protocols. However, although VIVID-DME and VISTA-DME were well-designed randomised clinical trials, this article reports findings from an exploratory post hoc analysis, and further prospective research is needed to confirm the current findings.

In conclusion, these post hoc analyses through week 100 demonstrate the benefits of intravitreal afibercept over laser in patients with DME regardless of baseline DR severity, suggesting that even patients with severe DR can experience visual and anatomical improvements after treatment with intravitreal afibercept.

Acknowledgements  Medical writing assistance was provided by Corey Eagan, MPH, of PAREXEL, and funded by Bayer.

Contributors  All authors meet the ICMJE criteria for authorship.

Funding  The VIVID-DME and VISTA-DME studies were supported by Bayer and Regeneron Pharmaceuticals, Inc.

Competing interests  GS is a consultant to Novartis, Bayer, Allergan, Genentech, Roche, Heidelberg Engineering, and Alcon. He has also received support for travel to meetings from Bayer HealthCare, Centervue, Heidelberg Engineering, and Novartis. He has received payment for lectures from Zeiss, and is a patent holder in conjunction with Ocular Instruments, Inc. He has received payment for development of educational presentations for Roche. NF is a consultant to Alimera, and has received funding from Novartis, Allergan, Alimera, Bayer, and Heidelberg Engineering. JJA is a member of advisory boards for Novartis, Bayer, and Allergan. She has received personal fees and others from Novartis and others from Bayer. TA Katz is an employee of Bayer. CM is an employee of Bayer. CL is an employee of Bayer. FGH is a consultant to Acucela, Genentech/Roche, Novartis, Bayer, Alcon, OPTOS, Heidelberg Engineering, Carl Zeiss Meditec, Allergan, and Pfizer, and has received financial support from OPTOS, Heidelberg Engineering, Carl Zeiss Meditec, Alcon, Genentech/ Roche, Bayer, and Novartis.

Ethics approval  Institutional Review Board/Ethics Committee approval was obtained at each site before the start of the studies.

Provenance and peer review  Not commissioned; externally peer reviewed.

Open Access  This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Boyer DS, Hopkins JL, Sorof J, et al. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013;4:151–69.
2. International Diabetes Federation IDF Diabetes Atlas. International diabetes federaton website. http://www.idf.org/diabetesatlas (accessed 19 Jan 2017).
3. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119:789–801.
4. Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119:2312–8.
5. Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 2014;121:1045–53.
6. Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol 2013;156:502–10.
7. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130:972–9.
8. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014;121:2247–54.
9. Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 2015;122:2044–52.
10. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:193–203.
11. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016;123:1351–9.
12. Jampol LM, Glassman AR, Bressler NM, et al. Anti-vascular endothelial growth factor comparative effectiveness trial for diabetic macular edema: additional efficacy post hoc analyses of a randomized clinical trial. JAMA Ophthalmol 2016;134.
13. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 1991;98(S Suppl):823–33.
14. American Academy of Ophthalmology, International Clinical Diabetic Retinopathy Disease Severity Scale detailed table. International Council of Ophthalmology website. http://www.icoph.org/dynamic/attachments/resources/diabetic-retinopathy-detail.pdf (accessed 20 Jan 2017).
15. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118:615–25.
16. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064–77.
17. Chong V, Mitchell P. Baseline predictors of 3-year responses to ranibizumab and laser photocoagulation therapy in patients with visual impairment due to diabetic macular edema (DME). Eur J Ophthalmol 2013;23:446–62.
18. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122–9.
19. Finger RP, Wickremasinghe SS, Baird PN, et al. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol 2014;59:1–18.